Results 281 to 290 of about 527,270 (344)
Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong +5 more
wiley +1 more source
PRKD1/EIF5A/β-catenin axis inhibits tumorigenesis and metastasis in non-small-cell lung cancer. [PDF]
Wang Y +7 more
europepmc +1 more source
This study identifies OCIAD2 as a critical regulator of cisplatin resistance in HNSCC. Mechanistically, OCIAD2 stabilizes integrin β1 through a direct physical interaction and facilitates its SNX17‐dependent endosomal recycling to lipid raft microdomains. Targeting OCIAD2 disrupts integrin β1 trafficking and significantly enhances cisplatin sensitivity,
Li Cui +9 more
wiley +1 more source
Epithelial HO-1 regulates iron availability and promotes colonic tumorigenesis in a context-dependent manner. [PDF]
Callahan RC +16 more
europepmc +1 more source
The functional schematic diagram of tumor associated neutrophils. Abstract Enhancing cervical cancer (CC) immunotherapy requires deciphering the heterogeneous tumor immune microenvironment (TIME), particularly neutrophil phenotypic dynamics. Here, 1) we collected 543 CC cases to find that patients with elevated neutrophil levels have a higher incidence
Xingyu Chang +7 more
wiley +1 more source
Tumor virus-induced lineage survival circuit drives Merkel cell carcinogenesis. [PDF]
Shuda M.
europepmc +1 more source
The LIN28B-IMP1 post-transcriptional regulon has opposing effects on oncogenic signaling in the intestine [PDF]
et al,, Madison, Blair B
core +1 more source
Lenvatinib resistance poses a major challenge in advanced hepatocellular carcinoma (HCC). This study reveals that DNMT2 upregulation is a key driver, which stabilizes ACLY mRNA via m5C modification and activates the Notch signaling pathway. Crucially, combining ACLY inhibitors with lenvatinib overcomes resistance and suppresses tumors, offering a ...
Shiguang Yang +14 more
wiley +1 more source

